<html>
<head>PUBMED IDs for SOLT</head>
<body bgcolor='#C5F0F2'><h1>SOLT</h1><a href='https://pubmed.ncbi.nlm.nih.gov/25559818/'>PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.</a> June 16  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/25851628/'>Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.</a> April 6  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/27684533/'>RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.</a> September 30  2016<br></body></html>
